Denali Therapeutics (DNLI) stock price, revenue, and financials

Denali Therapeutics market cap is $7.4 b, and annual revenue was $26.68 m in FY 2019

$7.4 B

DNLI Mkt cap, 20-Nov-2020

$9.4 M

Denali Therapeutics Revenue Q3, 2020
Denali Therapeutics Net income (Q3, 2020)-58.2 M
Denali Therapeutics EBIT (Q3, 2020)-60.1 M
Denali Therapeutics Cash, 30-Sept-2020351 M
Denali Therapeutics EV7.1 B

Denali Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

129.2m26.7m

Sales and marketing expense

5.1m11.7m15.7m

R&D expense

11.6m75.7m74.5m143.2m193.4m

General and administrative expense

32.3m46.5m

Operating expense total

16.7m87.4m90.1m175.5m239.9m

EBIT

(16.7m)(87.4m)(90.1m)(46.4m)(213.2m)

EBIT margin, %

(36%)(799%)

Interest expense

109.0k10.1m15.2m

Interest income

781.0k2.0m

Income tax expense

(351.0k)

Net Income

(16.8m)(86.7m)(88.2m)(36.2m)(197.6m)

Denali Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

39.9m218.4m77.1m79.4m

Prepaid Expenses

3.6m3.4m16.5m14.7m

Current Assets

182.0m409.6m480.8m430.0m

PP&E

15.3m14.9m25.2m46.7m

Total Assets

271.1m486.7m662.0m553.2m

Accounts Payable

2.0m2.7m1.9m2.6m

Current Liabilities

9.1m14.2m32.8m45.3m

Long-term debt

68.9m

Total Debt

68.9m

Total Liabilities

16.5m20.9m115.1m158.3m

Common Stock

344.0k1.2m1.3m1.3m

Preferred Stock

348.7m

Additional Paid-in Capital

9.4m656.7m774.2m818.8m

Retained Earnings

(103.5m)(191.7m)(227.9m)(425.6m)

Total Equity

(94.2m)465.8m546.8m394.9m

Financial Leverage

-2.9 x1 x1.2 x1.4 x

Denali Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(16.8m)(86.7m)(88.2m)(36.2m)(197.6m)

Depreciation and Amortization

121.0k1.5m3.1m8.0m

Accounts Payable

1.7m161.0k207.0k(526.0k)1.0m

Cash From Operating Activities

(15.1m)(72.4m)(76.6m)50.1m(151.6m)

Purchases of PP&E

(3.1m)(6.1m)(2.9m)(3.4m)(17.9m)

Cash From Investing Activities

(3.1m)(219.0m)(41.2m)(287.4m)147.7m

Dividends Paid

Cash From Financing Activities

48.9m300.5m296.3m97.0m6.2m

Net Change in Cash

30.7m9.1m178.5m(140.3m)2.3m

Quarterly

USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(23.7m)(78.4m)(113.8m)(39.0m)(56.8m)(115.5m)(173.7m)

Depreciation and Amortization

854.0k2.7m5.0m2.4m2.1m4.3m6.4m

Accounts Payable

(951.0k)7.1m1.2m2.0m(292.0k)(744.0k)147.0k

Cash From Operating Activities

33.6m(8.2m)(43.1m)(30.3m)(54.5m)(97.8m)(97.8m)

Purchases of PP&E

(537.0k)(1.1m)(2.0m)(2.0m)(879.0k)(1.2m)(1.9m)

Cash From Investing Activities

(301.3m)(270.7m)(226.0m)(8.0m)(13.3m)(43.7m)(255.9m)

Dividends Paid

Cash From Financing Activities

93.2m94.7m95.3m908.0k195.9m199.3m625.2m

Net Change in Cash

(174.5m)(184.3m)(173.8m)(37.5m)128.1m57.7m271.6m

Denali Therapeutics Ratios

USDFY, 2015

Denali Therapeutics Employee Rating

3.517 votes
Culture & Values
3.4
Work/Life Balance
2.5
Senior Management
3.2
Salary & Benefits
3.2
Career Opportunities
2.9
Source